U.S. FDA Removes 27 Ranbaxy Generic Applications As Part Of Decree
This article was originally published in PharmAsia News
The U.S. FDA removed 27 Ranbaxy Laboratories applications for since-withdrawn generics as prescribed by a consent decree with the company earlier this year.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.